LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Home・Akcijų sąrašas・Verve Therapeutics Inc

Verve Therapeutics Inc

Atidarymo kaina

4.64 8.41

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

4.22

Max

4.7

Pagrindiniai rodikliai
By Trading Economics
Pajamos	98K -50M
Pardavimai	6.2M 13M
Pelnas, tenkantis vienai akcijai	-0.58
Pelno marža	-382.531
Darbuotojai	274
EBITDA	789K -54M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+485.85% upside

Dividendai
By Dow Jones
Kitas uždarbis	2025-08-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-207M 388M
Ankstesnė atidarymo kaina	-3.77
Ankstesnė uždarymo kaina	4.64

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

4.1501 / 5.16 Palaikymas ir pasipriešinimas

Verve Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-05-15 22:52; UTC

Uždarbis

Pagrindinės rinkos jėgos

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

2025-05-15 20:37; UTC

Svarbiausios naujienos

Uždarbis

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

2025-05-16 00:00; UTC

Rinkos pokalbiai

Xero Bull Stays Positive on Cost Outlook -- Market Talk

2025-05-15 23:47; UTC

Rinkos pokalbiai

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

2025-05-15 23:38; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-05-15 23:38; UTC

Rinkos pokalbiai

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

2025-05-15 23:14; UTC

Svarbiausios naujienos

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

2025-05-15 22:46; UTC

Svarbiausios naujienos

Įsigijimai, susijungimai, perėmimai

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

2025-05-15 22:46; UTC

Įsigijimai, susijungimai, perėmimai

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

2025-05-15 22:46; UTC

Įsigijimai, susijungimai, perėmimai

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

2025-05-15 22:46; UTC

Įsigijimai, susijungimai, perėmimai

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

2025-05-15 21:58; UTC

Uždarbis

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

2025-05-15 21:24; UTC

Uždarbis

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

2025-05-15 20:56; UTC

Rinkos pokalbiai

U.S. Spending Downturn Could Lie Ahead -- Market Talk

2025-05-15 20:54; UTC

Rinkos pokalbiai

Uždarbis

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

2025-05-15 20:54; UTC

Uždarbis

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

2025-05-15 20:51; UTC

Uždarbis

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

2025-05-15 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-05-15 20:50; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

2025-05-15 20:50; UTC

Uždarbis

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

2025-05-15 20:47; UTC

Uždarbis

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

2025-05-15 20:47; UTC

Uždarbis

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

2025-05-15 20:47; UTC

Uždarbis

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

2025-05-15 20:47; UTC

Uždarbis

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

2025-05-15 20:37; UTC

Uždarbis

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

2025-05-15 20:37; UTC

Uždarbis

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

2025-05-15 20:37; UTC

Uždarbis

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

2025-05-15 20:37; UTC

Uždarbis

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

2025-05-15 20:26; UTC

Svarbiausios naujienos

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

2025-05-15 20:25; UTC

Uždarbis

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Verve Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

485.85% į viršų

12 mėnesių prognozė

Vidutinis 25.25 USD 485.85%

Aukščiausias 39 USD

Žemiausias 15 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Verve Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

Pirkti

Laikyti

Parduoti

Remiantis 10 analitikų, pateikusių Verve Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

4.1501 / 5.16Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Verve Therapeutics Inc

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.